Table 1.
Main demographics and clinical data of the participants in this study at baseline (day 0), before the administration of 2000 IU/day or 10,000 IU/day of cholecalciferol.
|
Supplementation group |
||||
|---|---|---|---|---|
| Characteristics | All | 2000 IU/day | 10,000 IU/day | p-value |
| (n = 85) | (n = 44) | (n = 41) | ||
| Age at diagnosis, median (IQR)— yr. | 65.0 (53.0–74.0) | 65.3 (44.0–72.3) | 67.0 (58.0–75.0) | 0.0665 |
| Time from onset of symptoms to hospitalization, median (IQR) — days | 7 (6–10) | 7 (6–9) | 7 (6–10) | 0.5440 |
| Gender | ||||
| Male— no. (%) | 60 (70.6) | 30 (68.2) | 30 (73.2) | 0.7901 |
| Female— no. (%) | 25 (29.4) | 14 (31.2) | 11 (26.8) | |
| Classification by BMI (kg/m2) | ||||
| Normal Weight (18.5–24.9) — no. (%) | 7 (8.2) | 4 (9.1) | 3 (7.3) | 0.7747 |
| Overweight (25.0–25.9) — no. (%) | 32 (37.6) | 15 (34.1) | 17 (41.5) | |
| Obesity (>30) — no. (%) | 46 (54.1) | 25 (56.8) | 21 (51.2) | |
| Smoker | ||||
| No — no. (%) | 57 (67.1) | 30 (68.2) | 27 (65.8) | 0.9260 |
| Former Smoker— no. (%) | 25 (29.4) | 13 (29.5) | 12 (29.3) | |
| Yes— no. (%) | 3 (3.5) | 1 (2.3) | 2 (4.9) | |
| Alcohol consumption | ||||
| No— no. (%) | 72 (84.7) | 38 (86.4) | 34 (82.9) | 0.8973 |
| Former drinker— no. (%) | 4 (4.7) | 2 (4.5) | 2 (4.9) | |
| Yes— no. (%) | 9 (10.6) | 4 (9.1) | 5 (12.2) | |
| Coexisting conditions | ||||
| Hypertension— no. (%) | 41 (48.2) | 18 (40.1) | 23 (56.1) | 0.2368 |
| Dyslipidemia— no. (%) | 31 (36.5) | 12 (27.3) | 19 (46.3) | 0.1097 |
| Diabetes— no. (%) | 19 (22.3) | 8 (18.2) | 11 (26.8) | 0.4866 |
| Pneumonia at Rx | ||||
| Unilateral — no. (%) | 12 (14.1) | 7 (15.1) | 5 (12.2) | 0.8574 |
| Bilateral— no. (%) | 73 (85.9) | 37 (84.1) | 36 (87.8) | |
| Blood biochemistry data | ||||
| Leucocytes, mean (SD)— mil/µL | 8.1 (4.3) | 7.3 (3.8) | 8.9 (4.7) | 0.0815 |
| Neutrophils, mean (SD)— mil/µL | 6.3 (4.0) | 5.7 (3.6) | 7.0 (4.4) | 0.1614 |
| Lymphocytes, mean (SD)— mil/µL | 1.2 (0.9) | 1.1 (0.5) | 1.4 (1.2) | 0.0646 |
| Treatments— no. (%) | ||||
| Dexamethasone | 56 (65.9) | 29 (65.9) | 27 (65.8) | 1 |
| Methylprednisolone | 21 (24.7) | 9 (20.45) | 12 (29.3) | 0.4903 |
| Tocilizumab | 21 (24.7) | 9 (20.45) | 12 (29.3) | 0.4903 |
| LMWH | 73 (85.9) | 36 (81.8) | 37 (90.2) | 0.4219 |
| Ceftriaxone | 50 (58.9) | 24 (54.5) | 26 (59.1) | 0.5421 |
| Azithromycin | 36 (42.35) | 20 (45.5) | 16 (39) | 0.7040 |
BMI, body mass index; IQR, interquartile range; LMWH, Low-molecular-weight heparin; no., number; SD, standard deviation; yr., year.